Cumberland Pharmaceuticals (CPIX) vs Foghorn Therapeutics (FHTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Cumberland Pharmaceuticals (CPIX) has outperformed Foghorn Therapeutics (FHTX) over the past year, gaining 108.7% versus a loss of 53.6%. Over five years, CPIX leads with a +167.9% price change compared with -85.4% for FHTX. Foghorn Therapeutics is the larger company by market cap ($109.9 million vs $107.6 million), about 1.0 times the size.
Cumberland Pharmaceuticals converts more of its revenue into profit, with a net margin of -6.4% versus -240.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPIX | FHTX |
|---|---|---|
| Share price | $7.18 | $1.85 |
| Market cap | $107.58M | $109.86M |
| 1-day change | -4.77% | -2.12% |
| YTD return | +80.40% | -65.74% |
| 1-year return | +108.72% | -53.63% |
| 5-year return | +167.91% | -85.43% |
| Forward P/E | 51.29 | — |
| EPS (TTM) | $-0.62 | $-0.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $44.52M | $30.91M |
| Revenue growth (YoY) | +17.57% | +36.75% |
| Net income (latest FY) | $-2.84M | $-74.28M |
| Gross margin | 85.02% | — |
| Operating margin | -6.27% | -279.49% |
| Net margin | -6.37% | -240.33% |
| 52-week high | $9.28 | $7.61 |
| 52-week low | $1.85 | $1.79 |
| Distance from 52-week high | -22.63% | -75.69% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +224.32% |
| Average volume | 76.95K | 672.05K |
| Shares outstanding | 14.98M | 59.39M |
| Employees | 88 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CPIX has outperformed FHTX by 162.4 percentage points over the past year.
- Cumberland Pharmaceuticals is more profitable, keeping -6.4 cents of every revenue dollar as net income versus -240.3 cents for Foghorn Therapeutics.
- Foghorn Therapeutics grew revenue faster in its latest fiscal year (+36.75% vs +17.57%).
About Cumberland Pharmaceuticals
CPIX stock →Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About Foghorn Therapeutics
FHTX stock →Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
CPIX vs FHTX FAQ
Which is bigger, Cumberland Pharmaceuticals or Foghorn Therapeutics?
Foghorn Therapeutics (FHTX) is larger, with a market capitalization of $109.86M compared with $107.58M for Cumberland Pharmaceuticals (CPIX).
Which stock has performed better over the past year, CPIX or FHTX?
CPIX returned +108.72% over the past 12 months, compared with -53.63% for FHTX (price return, excluding dividends). Past performance does not predict future results.
Are Cumberland Pharmaceuticals and Foghorn Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.